Table 1.

Summary of patient characteristics, clinical responses and toxicities after anti-CD19 CAR-T therapy in four patients.

Patients	Patient 1		Patient 2		Patient 3		Patient 4
Age	36		48		48		65
Sex	Male		Female		Female		Male
ECOG	4		2		2		1
Prior therapies	Induction therapy: MVP + imatinib Cycles of intrathecal injection Unrelated-HSCT		Induction therapy: DVLP + imatinib Cycles of consolidation therapy Cycles of intrathecal injection HD-MTX,HD-MTX + VP + imatinib		Induction therapy: VDCP Cycles of consolidation therapy Sib-HSCT		Induction therapy: IVP + nilotinib
Relapsed/refractor y status	1st CNS relapse postinduction therapy within 2 months; 2nd CNS relapse post-HSCT within 2 years		CNS relapse postconsolidation therapy + imatinib within 2 years		CNS relapse post-sib-HSCT within 4 months		In remission
Time (months) to progression or last follow-up	3 months to relapse		CR in 12 months		CR in 10 months		CR until now
Clinical response	Before	After	Before	After	Before	After	Before	After
Complaints	Headache, dizziness, fatigue, epileptic seizures, impaired consciousness	Visual loss	Headache, vomiting and visual loss	Visual loss	Double vision	Normal	Normal	Normal
Symptoms	Visual loss in both eyes, bilateral pupillary light reflex disappeared, left central facial palsy, bilateral Babinski's sign positive, limb muscle strength decreased	Visual loss in both eyes, left central facial palsy disappeared, bilateral Babinski's sign became negative, limb muscle strength improved (upper)	Normal	Normal	Left abducent paralysis	Normal	Normal	Normal
GCS score	9	15	15	15	15	15	15	15
NIHSS score	21	3	0	0	0	0	0	0
Barthel index	0	50	100	100	100	100	100	100
BM	CR	CR	CR	CR	CR	CR	CR	CR
Molecular	BCR/ABL 4294/10,000 abl copies	BCR/ABL <10/10,000 abl copies	BCR/ABL 33/10,000 abl copies	BCR/ABL 35/10,000 abl copies	MRD 2.5 × 10−4 by flow cytometry	MRD 0 × 10−4 by flow cytometry	MRD 5.7 × 10−4 by flow cytometry	MRD 0 × 10−4 by flow cytometry
CSF	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative
Molecular	BCR/ABL positive	BCR/ABL positive	BCR/ABL positive	BCR/ABL negative	MRD 2.47% by flow cytometry	MRD 0 × 10−2 by flow cytometry	BCR/ABL negative	BCR/ABL negative
MRI	Signal in the pontine parenchyma was slightly high and the end of the central aqueduct and four ventricle	The pontine dorsal swelling was significantly reduced and the degree of stenosis reduced	Negative	Negative	Pituitary tumor in the sellar region	Tumor almost disappeared	N/A	N/A
CRS grade	1		1		1		1
ICE score	9		10		10		10
ICANS grade	1		1		1		1